1. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study
- Author
-
Honey Saju, Arnab Bhattacharjee, Biswajit Dubashi, Dinesh Ravikumar, Amit Choudary, Prasanth Ganesan, and Smita Kayal
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,Incidence (epidemiology) ,Myeloid leukemia ,Retrospective cohort study ,030204 cardiovascular system & hematology ,Consolidation therapy ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Internal medicine ,medicine ,Cytarabine ,Original Article ,Prospective cohort study ,business ,030215 immunology ,medicine.drug - Abstract
BACKGROUND: Cytarabine based therapy has been the standard consolidation regimen for AML (acute myeloid leukemia) for decades. However, the optimal dose, regimen and schedule is not known. HIDAC (high dose cytarabine at 18 g/m(2)) has been the conventional standard, however, recent studies have shown that intermediate doses of cytarabine (IDAC) have equal efficacy and lesser toxicities. METHODS: We retrospectively analysed 75 AML patients who entered consolidation out of 167 patients who underwent induction therapy between 2014 and 2018. HIDAC (at 18 g/m(2)) was given to 39 patients and 36 patients received IDAC at 9 g/m(2). RESULTS: Median age was 28 years (range 2–60). Male: female ratio was 1.02. More courses were administered in out-patient setting in IDAC group 61% (n = 58/95 courses) than in HIDAC 29% (n = 29/101 courses); p
- Published
- 2021
- Full Text
- View/download PDF